UBS Group AG grew its holdings in Medpace Holdings Inc (NASDAQ:MEDP) by 2,869.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 323,307 shares of the company’s stock after purchasing an additional 312,420 shares during the quarter. UBS Group AG owned 0.91% of Medpace worth $11,286,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of MEDP. Schwab Charles Investment Management Inc. boosted its stake in shares of Medpace by 96.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 58,066 shares of the company’s stock valued at $2,106,000 after purchasing an additional 28,581 shares during the period. SG Americas Securities LLC purchased a new position in shares of Medpace in the fourth quarter valued at approximately $151,000. First Trust Advisors LP purchased a new position in shares of Medpace in the fourth quarter valued at approximately $1,545,000. Wells Fargo & Company MN boosted its stake in shares of Medpace by 90.3% in the fourth quarter. Wells Fargo & Company MN now owns 19,703 shares of the company’s stock valued at $714,000 after purchasing an additional 9,349 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Medpace by 16.1% in the fourth quarter. Bank of New York Mellon Corp now owns 72,010 shares of the company’s stock valued at $2,611,000 after purchasing an additional 10,010 shares during the period. 26.81% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:MEDP opened at $43.75 on Tuesday. The company has a market capitalization of $1.60 billion, a P/E ratio of 28.78, a PEG ratio of 1.70 and a beta of 0.22. Medpace Holdings Inc has a fifty-two week low of $26.56 and a fifty-two week high of $45.94. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.66 and a current ratio of 0.66.
Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 30th. The company reported $0.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.17. The firm had revenue of $108.40 million for the quarter, compared to analysts’ expectations of $113.12 million. Medpace had a net margin of 10.37% and a return on equity of 12.50%. The firm’s revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 earnings per share. analysts predict that Medpace Holdings Inc will post 1.89 earnings per share for the current fiscal year.
In related news, major shareholder Medpace Limited Partnership sold 3,000,000 shares of the firm’s stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $35.49, for a total value of $106,470,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 29.50% of the stock is owned by company insiders.
Several research analysts have recently commented on MEDP shares. Credit Suisse Group reissued an “outperform” rating and issued a $42.00 price objective (up previously from $41.00) on shares of Medpace in a research note on Tuesday, February 27th. Jefferies Financial Group reissued a “hold” rating and issued a $35.00 price objective on shares of Medpace in a research note on Thursday, March 1st. Mitsubishi UFJ Financial Group reissued a “neutral” rating and issued a $40.00 price objective on shares of Medpace in a research note on Friday, April 20th. Robert W. Baird set a $35.00 price objective on shares of Medpace and gave the company a “hold” rating in a research note on Tuesday, April 10th. Finally, Zacks Investment Research lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $37.83.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.